Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ: LEXX )

1.590 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
29 30 Next >
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Designing Human Clinical Study of DehydraTECH-CBD for Weight Loss, Diabetes Control
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Designing Human Clinical Study of DehydraTECH-CBD for Weight Loss, Diabetes Control
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
Via ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) Announces New Subsidiary, Provides Update on Nicotine Study
Via Investor Brand Network
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property
Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science
Via ACCESSWIRE
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Newly Granted Patent for DehydraTECH(TM)–Nicotine by United States Patent and Trademark Office
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Newly Granted Patent for DehydraTECH(TM)–Nicotine by United States Patent and Trademark Office
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Set to be Used in Multi-Billion Dollar Markets; On Track to have 2023 as Best Year Yet
Via CannabisNewsWire
Lexaria Receives New Patents
Via ACCESSWIRE
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Set to be Used in Multi-Billion Dollar Markets; On Track to have 2023 as Best Year Yet
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Publishes Eighth Peer-Reviewed Article in International Journal of Molecular Science
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Publishes Eighth Peer-Reviewed Article in International Journal of Molecular Science
Via Investor Brand Network
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Building a Robust and Growing International Patent Portfolio for DehydraTECH(TM) in Support of Commercial Opportunities
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Building a Robust and Growing International Patent Portfolio for DehydraTECH(TM) in Support of Commercial Opportunities
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery Sector
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
Via ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Study Reveals ‘Most Convincing Evidence’ of CBD’s Anti-Inflammatory Actions in Humans
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Increases Bioavailability in Lipophilic Drugs for Potential Hypertension, Epilepsy Treatments
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) – A Zacks Update
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen Hormone than Control
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Published Peer-Reviewed Article on DehydraTECH(TM)-CBD, Bringing Publication Total to Eight
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Published Peer-Reviewed Article on DehydraTECH(TM)-CBD, Bringing Publication Total to Eight
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Robust Intellectual Property Portfolio to 34 Worldwide Patents with Receipt of 4 New Granted in Canada, US
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands IP Portfolio with Four New Patents
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Promising Results from Diabetes Animal Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Promising Results from Diabetes Animal Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study
Via ACCESSWIRE
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) May Announcements Show Resolve to Continue Supporting R&D ‘Lifeblood’
Via Investor Brand Network
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.